SAKAR HEALTHCARE LIMITED
SAKAR · General/Diversified · NSE
₹803
Current Market Price
Fair Value (DCF)
₹295
Discount to FV
-63.3%
Updated just now
YieldIQ Score
40/100
Piotroski F-Score
7/9
Economic Moat
Moderate
Confidence
46%
ROE
6.1%
Debt/Equity
0.30
WACC
11.1%
Market Cap
₹1,762 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
13.5%
Return on capital employed
EV / EBITDA
24.6×
Enterprise multiple
Debt / EBITDA
0.8×
Leverage vs earnings
Interest Coverage
3.7×
EBIT covers interest
Current Ratio
1.40×
Short-term liquidity
Asset Turnover
0.61×
Revenue per ₹ of assets
Revenue CAGR (3Y)
23.6%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹802.95
Bear case
Discount -417.9%
Base case
Discount -172.1%
Bull case
Discount -134.2%
Ratio Trends
SAKAR · last 7 annual periods
ROE
6.1%
ROCE
13.5%
Operating Margin
—
Debt / Equity
0.30×
PE
112.3×
EV / EBITDA
12.1×
Historical Financials
SAKAR · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹128 Cr | ₹133 Cr | ₹153 Cr | ₹178 Cr | ₹252 Cr | +18.4% |
| EBITDA | ₹31.3 Cr | ₹37.3 Cr | ₹40.7 Cr | ₹50.9 Cr | ₹71.2 Cr | +22.8% |
| EBIT | ₹21.8 Cr | ₹22.8 Cr | ₹23.5 Cr | — | — | +1.9% |
| PAT | ₹15.2 Cr | ₹12.8 Cr | ₹11.7 Cr | ₹17.5 Cr | ₹30.5 Cr | +18.9% |
| EPS (diluted) | ₹8.73 | ₹6.59 | ₹5.63 | — | — | -10.4% |
| CFO | ₹24.6 Cr | ₹33.3 Cr | ₹24.5 Cr | ₹34.0 Cr | ₹49.3 Cr | +18.9% |
| CapEx | ₹-35.5 Cr | ₹-82.2 Cr | ₹-59.6 Cr | ₹-32.3 Cr | ₹-28.4 Cr | — |
| FCF | ₹-10.9 Cr | ₹-48.9 Cr | ₹-35.1 Cr | ₹1.7 Cr | ₹20.9 Cr | — |
| Total Assets | ₹268 Cr | ₹336 Cr | ₹389 Cr | ₹415 Cr | ₹481 Cr | +15.8% |
| Total Debt | ₹92.9 Cr | ₹119 Cr | ₹79.4 Cr | ₹86.4 Cr | ₹55.3 Cr | -12.2% |
| Shareholders' Equity | ₹127 Cr | ₹173 Cr | ₹262 Cr | ₹285 Cr | ₹324 Cr | +26.3% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
SAKAR vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
JAGSNPHARM JAGSNPHARM | — | — | Pending | 15.6% | 28.7× |
SYNCOMF SYNCOMF | — | — | Pending | 14.4% | — |
BETA BETA | — | — | Pending | 16.9% | — |
 VENUSREM VENUSREM | — | — | Pending | 8.1% | — |
 BAJAJHCARE BAJAJHCARE | — | — | Pending | 3.0% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for SAKAR in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. SAKAR HEALTHCARE LIMITED (SAKAR.NS) trades at 802.95 vs a model fair value of 295.04, a gap of -63.3%. Piotroski F-score: 7/9. Moat label...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of SAKAR →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for SAKAR →
Compare
Head-to-head with peers
Compare SAKAR side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse SAKARNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.